PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

In an interview with PharmaShots, Dave Marek. CEO of Myovant shares insights on the US FDA's approval of Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) in Uterine Fibroids. Shots: The US FDA has approved Myovant & Pfizer's Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as the first once-daily treatment for the…

BySenior EditorJuly 20, 2021

VIEWPOINTS

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

In an interview with PharmaShots, Myovant's Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP's positive opinion for Ryeqo (Relugolix Combination Tablet). Shots: The CHMP has adopted positive opinion recommending approval of Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of…

BySenior EditorJuly 5, 2021

TOP 20

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Life sciences companies are gearing up to enter new markets as they look to secure their positions after a spate of M&A- licensing- and research partnerships in 2020 Artios partnered with Merck with an option to license up to 8 oncology programs proving to be the highest valued deal of 2020 with a total deal…

ByPrince GiriJanuary 22, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2020

The US FDA has approved 7 NDAs and 2 BLA in Dec 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 105 novel products so far in 2020, including 9 in Dec 2020. Additionally, last year in 2019, the US FDA has approved…

BySenior EditorJanuary 21, 2021

PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Insights+: The US FDA New Drug Approvals in December 2020

Contact US

OUR INFORMATION

FOLLW US

PharmaShots Interview: Myovant’s Dave Marek Shares Insights on the US FDA’s Approval of Myfembree in Uterine Fibroids

PharmaShots Interview: Myovant’s Juan Camilo Arjona Ferreira Shares Insights on the Ryeqo

Top 20 Life Sciences Deals of 2020 by Total Deal Value

Insights+: The US FDA New Drug Approvals in December 2020

FOLLW US

Sign Up to Our Newsletter